内容概要：随着国民健康意识的提升，健康监测不再局限于生病后的就医检测，日常体检、慢性病管理 成为常态，这使得体检中心、社区卫生服务中心对尿液分析仪的需求持续增加，同时，人口老龄化加 剧，糖尿病、肾病等慢性病患者数量增多，这类患者需要长期进行尿液检测以监测病情，推动了医疗机 构和家庭对尿液分析仪的刚性需求，此外，养老机构、社区康养中心等新兴场景的兴起，也进一步拓展 了尿液分析仪的应用边界，据比地招标网数据显示，2024年我国尿液分析仪采购总量达1521台，同比增 长0.20%；采购均价为5.33万元/台；采购总金额达0.81亿元，与2023年基本持平，其中，华东地区占比 最大，高达33.7%，其次为华北地区和华中地区，分别占18.3%和14.4%。 上市企业：迪瑞医疗（300396）、迈瑞医疗（300760）、爱威科技（688067）、康泰医学（300869） 相关企业：桂林优利特电子集团有限公司、希森美康医用电子（上海）有限公司、深圳市美侨医疗科技 有限公司、艾康生物技术(杭州)有限公司、爱科来医疗科技（平湖）有限公司、安徽惠邦生物工程有限 公司、澳瑞（江西）科技有限公司、北京宝灵曼阳光科技有限公司、北京华晟 ...

Group 1: Company Overview and Market Position - The company is recognized as one of the earliest domestic enterprises in China to develop and manufacture medical monitoring devices, designated as a "National Multi-parameter Monitoring Instrument Industrialization Base" by the National Development and Reform Commission [1] - The company positions itself as a "critical care pioneer," focusing on high-end monitoring equipment primarily for ICU, anesthesia, and operating rooms, emphasizing high prices, added value, and technical barriers [1] - The P series plug-in monitor has won the "Red Dot Award" and features industry-leading anti-electrosurgical interference technology, intelligent early warning, high-end parameter integration analysis, and smart voice assistance [1] Group 2: Product Development and Innovation - The company plans to continue focusing on clinical needs, leveraging over 30 years of industry experience to enhance technological innovation and integrate smart solutions into product development [2] - New products will address core clinical pain points and feature "new quality" attributes, transitioning medical devices from "functional integration" to "intelligent decision-making" [2] Group 3: International Sales and Market Expansion - The company's blood dialysis products have entered overseas markets, with a 121.29% increase in overseas blood dialysis revenue in the first half of 2025, indicating positive growth [3] - The company aims to actively seize opportunities to expand its overseas blood dialysis market presence [3] Group 4: Regulatory Impact and Market Growth - The National Healthcare Security Administration's new pricing guidelines for blood dialysis services include monitoring items such as blood temperature and blood pressure, which the company's D800 series dialysis equipment can meet without additional modules [4] - The blood dialysis market has maintained a stable annual compound growth rate of approximately 12% over the past decade, with 1.027 million patients undergoing dialysis in 2024 [5] - The domestic blood dialysis equipment market saw sales growth in the first three quarters of 2025, driven by hospital operational recovery and centralized procurement [6] Group 5: New Product Launches and Financial Performance - Recent product launches include peritoneal dialysis machines, S series infusion pumps, electronic urine measuring devices, and telemetry monitors, enhancing the life information and support product line [6] - The subsidiary Suzhou Junkang reported revenue of 74.146 million yuan in the first three quarters of 2025, with plans to increase new product development and market expansion efforts [6]

Company Overview - Guangdong Baolait Medical Technology Co., Ltd. was established in 1993, focusing on the R&D, production, and sales of medical devices. It is recognized as a "National Multi-parameter Monitor Industrialization Base" and a "National Manufacturing Single Champion Enterprise" [1][2]. - The company’s monitoring equipment is utilized in thousands of medical institutions across China [1]. Product Categories - The company offers a diverse range of monitoring products, including integrated monitors, modular monitors, and handheld monitors, as well as infusion pumps, ECG machines, and central monitoring systems [2]. - In the renal medical field, Baolait has a complete industrial chain with eight consumable bases and a channel platform, providing products for blood dialysis and peritoneal dialysis [2]. Financial Performance - In the first half of 2025, the company achieved a revenue of CNY 523.44 million, a year-on-year decrease of 2.43%. However, the net profit attributable to shareholders increased by 152.22% to CNY 1.31 million [3]. - Total assets at the end of the reporting period were CNY 2.41 billion, a decrease of 3.66% from the beginning of the year [3]. R&D and Innovation - The company is focusing on clinical needs and technological innovation, aiming to integrate smart technology into product development to address core clinical pain points [4]. - Baolait's high-end monitoring products feature unique parameters and advanced technologies, enhancing their competitiveness in the market [5]. Market Demand and Opportunities - The number of blood dialysis patients in 2024 is projected to be 1.027 million, maintaining a compound annual growth rate of approximately 12% over the past decade [6]. - The company is actively expanding into the home dialysis market, particularly automated peritoneal dialysis, which has shown a growth rate of over 10% in recent years [7]. International Expansion - Baolait's blood dialysis products have begun to penetrate overseas markets, with a reported revenue growth of 121.29% in the first half of 2025 [8]. - The company is monitoring new policies related to blood dialysis and has developed products that meet the latest regulatory requirements [8]. New Product Launches - Recent product launches include peritoneal dialysis machines and smart monitoring devices, enhancing the company's product line in life information and support [8]. - The BioView C100 visual laryngoscope and S200 smart enteral nutrition pump were showcased at CMEF, featuring advanced imaging and safety features [8].

报告发布方：中金企信国际咨询 项目可行性报告&商业计划书专业权威编制服务机构（符合发改委印发项目可行性研究报告编制要求）-中金企信国际咨询：集13年项目编制服务经验为各 类项目立项、投融资、商业合作、贷款、批地、并购&合作、投资决策、产业规划、境外投资、战略规划、风险评估等提供项目可行性报告&商业计划书编 制、设计、规划、咨询等一站式解决方案。助力项目实施落地、提升项目单位申报项目的通过效率。 一、市场规模与增长趋势 根据中金企信数据显示，近年来全球医用骨盆牵引器市场规模持续扩大。2024年全球医用骨盆牵引器市场规模大约为419百万美元，预计2031年达到811百万 美元，2025-2031期间年复合增长率（CAGR）为10.0%。 数据整理：中金企信国际咨询 这一增长趋势主要得益于以下几个因素。首先，医疗技术的不断进步使得骨盆牵引器的功能更加完善，治疗效果更加显著，从而吸引了更多的患者和医疗机 构选择使用。例如，一些新型的牵引器采用了智能化的控制系统，能够根据患者的具体情况自动调整牵引力和牵引角度，大大提高了治疗的精准度和安全 性。其次，随着人们健康意识的提高，对于骨盆疾病的早期诊断和治疗需求也在增加，这进 ...

Company Overview - Guangdong Baolait Medical Technology Co., Ltd. was established in 1993, focusing on the R&D, production, and sales of medical devices. It is recognized as a "National Multi-parameter Monitor Industrialization Base" and a "National Champion Enterprise" in manufacturing [1][2]. Product Range - The company offers a diverse range of monitoring products, including integrated monitors, modular monitors, and handheld monitors, as well as infusion pumps, ECG machines, and central monitoring systems, widely used in various medical settings [2]. - In the nephrology sector, Baolait has a comprehensive product line including hemodialysis machines, dialyzers, and peritoneal dialysis equipment, catering to both acute and chronic renal failure treatments [2]. Financial Performance - In Q1 2025, the company reported a revenue of ¥247,732,813.14, a decrease of 7.17% from ¥266,864,471.78 in the same period last year. However, net profit attributable to shareholders increased by 298.35% to ¥14,448,489.46 [3]. Policy Impact - The new "old-for-new" equipment policy positively impacts the company's monitoring device business by increasing demand for updated equipment in public hospitals and grassroots medical institutions [4][5]. - The policy is expected to enhance the procurement of mid-to-high-end monitoring devices and blood dialysis equipment, benefiting from potential financial subsidies or tax incentives [5]. Market Opportunities - The number of hemodialysis patients in 2024 is projected to be 1.027 million, maintaining a stable annual growth rate of approximately 12% over the past decade. The demand for hemodialysis is expected to remain consistent due to the stable incidence of chronic kidney disease [6]. - There is significant potential for domestic product replacement in the hemodialysis market, with increasing preference for local dialysis equipment [6]. International Expansion - The company has begun to expand its blood dialysis product sales overseas, although the scale remains small. Future efforts will focus on seizing opportunities in the international blood dialysis market [7]. Production Capacity - The production capacity for dialyzers is primarily located in Suzhou and Zhuhai, with additional facilities across various regions in China for other dialysis-related products [8]. Innovations in Peritoneal Dialysis - The company has developed the PD600 peritoneal dialysis device, which features remote monitoring capabilities and user-friendly design, enhancing patient convenience for home treatment [9][10]. R&D Focus - The company aims to innovate in the life information and support sector by integrating intelligent technology into product development, addressing clinical needs, and advancing the development of high-end monitoring devices and dialysis-related products [12].

Financial Performance - In Q1 2025, the company's operating revenue was 247,732,813.14 CNY, a decrease of 7.17% compared to the same period last year [5] - The net profit attributable to shareholders was 14,448,489.46 CNY, showing a significant increase of 298.35% year-on-year [5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 338,833.92 CNY, up 105.49% from the previous year [5] - Basic earnings per share reached 0.0546 CNY, reflecting a year-on-year growth of 298.54% [5] Market and Policy Impact - The implementation of new policies, such as the "Action Plan for Promoting Large-Scale Equipment Updates and Consumer Goods Replacement," is expected to positively impact the company's monitoring and dialysis product lines [2] - Increased demand for monitoring equipment is anticipated due to the policy-driven replacement of outdated devices in public hospitals and grassroots medical institutions [2] - The company aims to leverage these policies to enhance market share through product upgrades and expanded marketing efforts [2] Industry Trends - The blood dialysis market is projected to experience increased competition over the next 3-5 years, with market concentration expected to rise as leading companies consolidate their positions [3] - Technological advancements, such as home dialysis and smart monitoring, are anticipated to become new growth points, favoring early adopters [4] - The emergence of new markets, particularly in China and India, is expected to challenge international giants as local companies offer competitive pricing [4] Product Development and Innovation - The company plans to focus on developing intelligent medical devices that address clinical needs, with an emphasis on innovative solutions in the renal care sector [5] - New products, including a polypropylene blood dialysis device and specialized dialysis solutions, are set to be launched in 2024 [4] - The company is also working on a new CRRT machine that will integrate with its overall life support solutions [5] Revenue Breakdown - In 2024, the life information and support segment generated sales revenue of 243,502,800 CNY, accounting for approximately 23% of total revenue [6] - The renal medical segment achieved sales revenue of 804,300,500 CNY, representing about 76% of total revenue [6] Strategic Focus for 2025 - The company will concentrate on its two main business areas, aiming to capitalize on opportunities from medical infrastructure expansion and domestic product substitution [8] - Plans include enhancing the penetration of high-margin products in critical care and surgical anesthesia [8] - The company will also strengthen its supply chain and production efficiency to align with procurement policies and improve overall operational effectiveness [8]